Amgen

Amgen And LabCentral Open Nomination Process For Lab Residency

Retrieved on: 
Wednesday, September 5, 2018
LabCentral, Amgen, Economy of the United States, Biotechnology

CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies.
  • "Opening the nomination process for the next Golden Ticket winners is always an exciting time for Amgen," said Aine Hanly, vice president of Process Development and Amgen Massachusetts site head.
  • During the 2018 Golden Ticket nomination process, Amgen will sponsor up to two promising life-sciences and biotech startup companies to reside in LabCentral's facilities.
  • In 2017, it also added the LabCentral Learning Lab for STEM programming to help inspire the next generation of science entrepreneurs.

Cumberland Pharmaceuticals Appoints New Senior Executive

Retrieved on: 
Monday, August 13, 2018
Amgen, Biotechnology, Pharmaceutical industry, Health, Economy of the United States

NASHVILLE, Tenn., Aug. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) today announced the appointment of biopharmaceutical industry veteran Adam Haeberle, Ph.D. as senior director, clinical and regulatory affairs.

Key Points: 
  • NASHVILLE, Tenn., Aug. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) today announced the appointment of biopharmaceutical industry veteran Adam Haeberle, Ph.D. as senior director, clinical and regulatory affairs.
  • Dr. Haeberle joins Cumberland from Amgen Inc., the world's largest biopharmaceutical company, where he held a series of director-level clinical development roles, including development clinical director.
  • At Amgen, he led clinical development initiatives and was responsible for innovating and increasing the overall efficiency of Amgen's cardiovascular portfolio.
  • Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care.

Job opportunities open for West Coast creative professionals as global marketing services company growth continues

Retrieved on: 
Wednesday, August 1, 2018
WLT, Sourcing, Amgen

WLT recently became the provider of creative production for Amgen's US marketing initiatives including print, digital and video.

Key Points: 
  • WLT recently became the provider of creative production for Amgen's US marketing initiatives including print, digital and video.
  • The company will also manage sourcing and fulfillment of printed marketing materials.
  • WLT continues to grow a West Coast center of excellence for its services and further expands its business through decoupling creative production from the traditional marketing agency model.
  • "WLT is looking forward to continuing our West Coast expansion and being a part of the Thousand Oaks community."

Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island

Retrieved on: 
Tuesday, July 31, 2018
Providence metropolitan area, New England, RHODE ISLAND, United States, Amgen, National Register of Historic Places in Providence, Rhode Island

"We are thrilled that Amgen has selected Rhode Island as the location for this plant that will be the first-of-its-kind in the United States," said Governor Gina M. Raimondo.

Key Points: 
  • "We are thrilled that Amgen has selected Rhode Island as the location for this plant that will be the first-of-its-kind in the United States," said Governor Gina M. Raimondo.
  • Amgen expects to invest up to $200 million in the approximately 120,000 square foot next-generation manufacturing plant in Rhode Island.
  • "Since its inception in 2002, Amgen Rhode Island has evolved to a multi-product manufacturing facility, which is a testament to our focus on innovation, technology and great staff," said Tia Bush, vice president of Operations at Amgen Rhode Island.
  • Since 2004, the Amgen Foundation has committed over $4.8 million to support science education and community programs in Rhode Island.

Pfizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market

Retrieved on: 
Tuesday, July 31, 2018
Membrane technology, Medicine, Erythropoiesis-stimulating agents, Chemistry, Clinical medicine, Methoxy polyethylene glycol-epoetin beta, Vifor Pharma, Dialysis, Amgen

Vifor Pharma, which also holds exclusive US commercialization rights to Roche's Mircera, a long-acting ESA, will be responsible for Retacrit commercialization in the US dialysis setting.

Key Points: 
  • Vifor Pharma, which also holds exclusive US commercialization rights to Roche's Mircera, a long-acting ESA, will be responsible for Retacrit commercialization in the US dialysis setting.
  • However, a growing preference for long-acting ESAs, Amgen's Aranesp and Mircera, may present an uphill battle.
  • Indeed, the most significant shift observed this quarter in the dialysis setting is the expansion of Mircera into small/medium dialysis organizations.
  • Spherix Global Insights is an independent market intelligence agency, specializing in renal, autoimmune, neurologic and rare disease markets.

Amgen Announces Succession Plans For Two Executive Officers

Retrieved on: 
Thursday, July 26, 2018
Amgen, Conejo Valley, Thousand Oaks, California, Vice President of the United States, President of the United States, Hooper, Geography of California, Biotechnology, Economy of the United States

THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.

Key Points: 
  • THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.
  • David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen, has been appointed as executive vice president of Research and Development, effective today.
  • In September 2018, Anthony C. Hooper, currently executive vice president of Global Commercial Operations, will retire from this role.
  • Hooper will also remain at Amgen for a period of time to facilitate the transition to Gordon.

Amgen Announces Webcast of 2018 Second Quarter Financial Results

Retrieved on: 
Tuesday, July 24, 2018
Amgen, Economy of the United States, Robert A. Bradway, NASDAQ, Thousand Oaks, California, Pharmaceutical industry, Business

THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.S. financial markets.

Key Points: 
  • THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.S. financial markets.
  • Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • The webcast will be archived and available for replay for at least 90 days after the event.

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

Retrieved on: 
Wednesday, July 18, 2018
Amgen, Multiple myeloma, Biotechnology, Health, Lisa Ray

I'm honored to work with Amgen on Myeloma MVP to help raise awareness of this incurable blood cancer and encourage patients to create a plan for managing their disease."

Key Points: 
  • I'm honored to work with Amgen on Myeloma MVP to help raise awareness of this incurable blood cancer and encourage patients to create a plan for managing their disease."
  • The multiple myeloma treatment landscape has evolved significantly over the past decade, changing the expectations of physicians and patients.
  • In order to create the right plan, patients need to have a voice in their treatment.
  • I look forward to working with Amgen, Dave and Steve to help bring awareness to this new tool for patients."

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA

Retrieved on: 
Friday, July 13, 2018
Medicine, RTT, Osteopathies, Clinical medicine, Monoclonal antibodies, Amgen, Health, Osteoporosis, Medication-associated osteonecrosis of the jaw, Bone fracture, Denosumab, Abaloparatide

"We look forward to continuing our work with the FDA to demonstrate the benefit:risk profile for EVENITY.

Key Points: 
  • "We look forward to continuing our work with the FDA to demonstrate the benefit:risk profile for EVENITY.
  • EVENITY is an investigational bone-forming monoclonal antibody and is not approved by any regulatory authority for the treatment of osteoporosis.
  • EVENITY has been studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program.
  • This program included two large fracture trials comparing EVENITY to either placebo or active comparator in more than 11,000 postmenopausal women with osteoporosis.Amgenand UCB are co-developing EVENITY.

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers

Retrieved on: 
Wednesday, June 27, 2018
Amgen, Workplace, Employee benefits, Business, Economy, Biotechnology

This marks the first Amgen partnership with an employee benefit consultant (EBC) and is Amgen's first migraine-specific project with employers.

Key Points: 
  • This marks the first Amgen partnership with an employee benefit consultant (EBC) and is Amgen's first migraine-specific project with employers.
  • Amgen and Piper Jordan will launch a migraine disease management program, "Manage My Migraine," to several large employers representing more than 50,000 employees across multiple industries.
  • "Both Amgen and Piper Jordan are committed to better understanding the burden of migraine and addressing stigma in the workplace."
  • Piper Jordan manages population health programs for national, large market employers across the U.S., representing employees across a multitude of industries.